← All protocols
Grade AApprovedwarningBioGate · AMBER

Metabolic Reset - GLP-1 Anchored

Type 2 diabetes adjunct + obesity (BMI ≥ 30 or BMI ≥ 27 with comorbidity)

semaglutide ↗
Protocol card

Eight audiences, one source of truth.

For clinicians

Dose & cycle

Semaglutide 0.25 mg → 0.5 mg → 1.0 mg → 2.0 mg SC weekly titration

Cycle
Continuous, 16-week titration
Duration
68 weeks per STEP-1 protocol
For patients

Monitoring endpoints

  • ✓HbA1c
  • ✓weight
  • ✓lipase
  • ✓CGM TIR
  • ✓Oura resting HR
Contraindications
  • ✕personal/family history of MTC
  • ✕MEN-2
  • ✕pregnancy
  • ✕active gallbladder disease
Jurisdiction gates
US ✓
FDA approved (Wegovy/Ozempic)
EU ✓
EMA approved
UK ✓
MHRA approved
AU ✓
TGA approved
Constituent peptides

Provenance, attestations, and structures.

SemaglutidewarningBioGate · AMBER
Loading Mol* bundle…
HXEGTFTSDVSSYLEGQAAKEFIAWLVRGRG

GLP-1 receptor agonist with extended half-life (~7 days); stimulates glucose-dependent insulin secretion and central appetite suppression.

IP economics

Cohort outcomes feed the royalty cascade.

Every revealed OEA from this protocol's cohorts updates the upstream IPNFT's outcome posterior. Holders receive pro-rata royalties from licensing, lab-fee escrow, and approved CRO contracts. Peptide MD does not custody the IPNFT; it indexes it through the Molecule registry.

IPNFT · Molecule IPNFT V2Solana
Semaglutide
4c0306…134702
Royalty cascade
13.88%
Holders
18
Royalty cascade routes lab fees, licensing, and OEA-attested cohort revenues back to holders, the cohort treasury, and the originating researchers in a 60 / 25 / 15 split.
Citations

Every claim, traceable.

Grade A2021 · N Engl J Med

Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)

Wilding JPH et al.

DOI 10.1056/NEJMoa2032183